Breaking News Instant updates and real-time market news.

INFI

Infinity Pharmaceuticals

$1.80

-0.02 (-1.10%)

, AGIO

Agios Pharmaceuticals

$79.81

0.95 (1.20%)

08:37
08/07/18
08/07
08:37
08/07/18
08:37

Infinity Pharmaceuticals appoints Samuel Agresta as Chief Medical Officer

Infinity Pharmaceuticals (INFYI) announced that it has appointed Samuel Agresta, as Chief Medical Officer where he will oversee global clinical development and regulatory affairs for the company. Agresta brings more than 20 years of experience in the practice of academic medicine and oncology drug development, including the recent approvals of two targeted therapies for the treatment of acute myeloid leukemia. Agresta joins Infinity from Agios Pharmaceuticals (AGIO), where he played a pivotal role in the development of the company's oncology programs, including IDHIFA and TIBSOVO, as Vice President and Head of Clinical Development.

INFI

Infinity Pharmaceuticals

$1.80

-0.02 (-1.10%)

AGIO

Agios Pharmaceuticals

$79.81

0.95 (1.20%)

  • 07

    Aug

  • 13

    Aug

  • 21

    Aug

INFI Infinity Pharmaceuticals
$1.80

-0.02 (-1.10%)

10/12/17
WELS
10/12/17
UPGRADE
Target $5
WELS
Outperform
Infinity upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Infinity Pharmaceuticals to Outperform and raised his price target for the shares to $5.00 from $1.50. The upgrade follows the selection of IPI-549 monotherapy data as a late breaker oral presentation at the Society of Immunotherapy of Cancer annual meeting in early November. The data have a "reasonable likelihood" of proof-of-concept response rate, and with likely validation of tumor macrophage targeting in immunooncology and a unique mechanism of action, upside potential is not reflected in the current stock price, Birchenough tells investors in a research note.
10/12/17
10/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Delta Air Lines (DAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying the company is likely to grow unit revenues in fiscal year 2018 due to pricing power in its key domestic hubs and improving international results. 2. Transocean (RIG) upgraded to Buy from Neutral at Citi with analyst Scott Gruber saying if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 3. Canadian Pacific (CP) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he sees a shift to stronger volume growth as the company laps contract losses and records some new contract wins. 4. Infinity upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough saying the IPI-549 monotherapy data have a "reasonable likelihood" of proof-of-concept response rate, and with likely validation of tumor macrophage targeting in immunooncology and a unique mechanism of action, upside potential is not reflected in the current stock price. 5. Kroger (KR) upgraded to Equal Weight from Underweight at Stephens with analyst Ben Bienvenu saying he believes the pursuit of strategic alternatives for the convenience store business has potential to unlock value and that the risk/reward is more balanced following the stock's recent pullback. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/31/18
GHSC
05/31/18
INITIATION
Target $4
GHSC
Buy
Infinity Pharmaceuticals initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Infinity Pharmaceuticals with a Buy and $4 price target. The analyst believes 2018 could be a "break-out" year with new data on its lead compound IPI-549 in combination with Opdivo for various tumor types with June 4 at ASXO form its "dose escalation" cohort, Q2 initial data from the "dose expansion" cohort, and more mature data from the "dose expansion" later in the year.
05/31/18
05/31/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wyndham Hotels & Resorts (WH) initiated with a Buy at Jefferies and an Overweight at JPMorgan. 2. Nxt-ID (NXTD) initiated with a Buy at Euro Pacific. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at Seaport Global. 4. Edwards Lifesciences (EW) and Medtronic (MDT) were initiated with an Outperform at Raymond James. 5. Rollins (ROL) initiated with a Hold at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AGIO Agios Pharmaceuticals
$79.81

0.95 (1.20%)

06/04/18
JPMS
06/04/18
NO CHANGE
JPMS
Overweight
JPMorgan says Agios data reinforces additive benefit potential of ivosidenib
JPMorgan analyst Anupam Rama said updates from the phase 1b trial center on the ivosidenib combination arm includes an incremental increase in ORR and in-line CR rates with larger patient dataset, which reinforces his view of the potential for meaningful additive benefit from IDH inhibition on top of azacitidine. Rama added that he did not see any major incremental safety concerns in the data. Rama has an Overweight rating on Agios shares, which are down nearly 11% in morning trading.
06/04/18
PIPR
06/04/18
NO CHANGE
PIPR
Overweight
Agios' ivosidenib combo data support use in frontline AML, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren noted that the combo of ivosidenib plus Vidaza demonstrated "robust" clinical activity, including the rough doubling of ORR and CR rates compared to Vidaza monotherapy, and he believes the data shared at ASCO are supportive of the combination being used in the frontline AML setting. If these earlier trial results are replicated in the AGILE Phase 3 study, Van Buren sees a high probability of this combo being approved and used in the frontline AML setting, he tells investors. He maintains an Overweight rating on shares of Agios Pharmaceuticals, which are down 5% to $91.92 in afternoon trading.
07/22/18
PIPR
07/22/18
NO CHANGE
Target $125
PIPR
Overweight
Agios' Tibsovo approved earlier, launch should go well, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that Agios (AGIO) announced the FDA approval of Tibsovo for relapsed/refractory acute myeloid leukemia, which represents the company's second approved drug product within the past year. The analyst points out that both Tibsovo and Idhifa, which was approved August 2017, cover approximately 20% of all AML patients who harbor IDHm mutations. Due to partner Celgene (CELG) and Agios' existing Idhifa launch efforts and the strong awareness of and similarity between both products, Van Buren expects the Tibsovo launch to be as good as - if not better - than the early Idhifa launch. Over time, he believes that Tibsovo can treat the majority of U.S; AML patients with IDH1 mutations and generate sales approaching $150M. The analyst reiterates an Overweight rating and $125 price target on Agios shares.
08/02/18
PIPR
08/02/18
NO CHANGE
Target $125
PIPR
Overweight
Agios launch of Tibsovo should be as good as Idhifa, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says he continues to believe that Agios Pharmaceuticals' (AGIO) launch of Tibsovo will be as good as, if not better, than the early Idhifa launch due to partner Celgene (CELG). Van Buren adds that while he "only" models $250M of U.S. sales in acute myeloid leukemia, the drug in this setting "could conceivably end up being several fold larger." Additionally, Agios management is being "appropriately vague" with the details of the dose-escalation in the ongoing Phase I study for AG-270, investors should be mindful of the fact that a response could be observed any day, which could be "very significant for the stock," Van Buren writes. The analyst keeps an Overweight rating on Agios Pharmaceuticals with a $125 price target.

TODAY'S FREE FLY STORIES

01:45
08/16/18
08/16
01:45
08/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

AVLR

Avalara

$34.68

-1.375 (-3.81%)

23:51
08/15/18
08/15
23:51
08/15/18
23:51
Upgrade
Avalara rating change at Goldman Sachs »

Avalara upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$70.61

-0.56 (-0.79%)

23:22
08/15/18
08/15
23:22
08/15/18
23:22
Hot Stocks
SK Telecom deploys Xilinx FPGAs for AI acceleration »

Xilinx jointly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVC

Invacare

$16.50

0.15 (0.92%)

21:30
08/15/18
08/15
21:30
08/15/18
21:30
Downgrade
Invacare rating change at KeyBanc »

Invacare downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change at KeyBanc »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated at UBS »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated at UBS »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated at UBS »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated at UBS »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated at UBS »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated at UBS »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated at UBS »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated at UBS »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated at UBS »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated at UBS »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated at UBS »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated at UBS »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated at UBS »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.